Acesso livre
Acesso livre

Covid-19 (Temas de Saúde Pública)

[Preprint] Covid-19: intervalo mais longo entre as doses da vacina da Pfizer aumenta a resposta imune.

27 Jul, 2021 | 10:34h

Comunicado de imprensa: Longer interval between Covid-19 Pfizer vaccine doses boosts immunity – Newcastle University

Estudo original (preprint): Sustained T cell immunity, protection and boosting using extended dosing intervals of BNT162b2 mRNA vaccine

Comentários:

Commentary: Covid-19: Longer interval between Pfizer doses results in higher antibody levels, research finds – BMJ

Expert reaction to preprint from PITCH study looking at interval between two Pfizer vaccine doses, and antibody and T-cell responses – Science Media Centre

Conteúdo Relacionado:

Debate: Should we delay second vaccine doses to give one dose of the Covid-19 vaccine to more people? (vários textos sobre o tema)

Outro estudo mostra resposta imune aumentada com vacinação heteróloga Oxford-AstraZeneca/mRNA.

27 Jul, 2021 | 10:32h

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination – Nature Medicine

Comentário: A ‘mix and match’ approach to SARS-CoV-2 vaccination – Nature Medicine

Conteúdos Relacionados:

WHO warns against mixing and matching COVID vaccines.

Germany issues world’s strongest recommendation for mixing Covid-19 vaccines.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Comentário no Twitter

 

Opinião | O que realmente significa saúde pública? Lições da Covid-19.

27 Jul, 2021 | 10:31h

What does public health really mean? Lessons from covid-19 – The BMJ Opinion

 

Comentário no Twitter (fio – clique para saber mais)

 

Grandes grupos médicos dos Estados Unidos pedem que os empregadores imponham a vacinação contra Covid-19 aos trabalhadores da área da saúde.

27 Jul, 2021 | 10:30h

Major medical groups call for employers to mandate Covid-19 vaccines for health care workers – CNN

Documento original: Joint Statement in Support of COVID-19 Vaccine Mandates for All Workers in Health and Long-Term Care

 

Comentários no Twitter

 

[Preprint] Estudo observacional | Efetividade da vacina Oxford-AstraZeneca em idosos durante a transmissão da variante Gama do SARS-CoV-2 no Brasil – A efetividade ajustada foi de 77,9% para Covid-19 sintomática, 87,6% contra hospitalização e 93,6% contra morte.

27 Jul, 2021 | 10:26h

Effectiveness of the ChAdOx1 vaccine in the elderly during SARS-CoV-2 Gamma variant transmission in Brazil – medRxiv

 

Comentário no Twitter (fio – clique para saber mais)

 

[Preprint] Estudo observacional | Efetividade da vacina CoronaVac em idosos durante a transmissão da variante Gama do SARS-CoV-2 no Brasil – A efetividade ajustada foi de 41,6% para Covid-19 sintomática, 59% contra hospitalização e 71,4% contra morte.

27 Jul, 2021 | 10:25h

Effectiveness of the CoronaVac vaccine in the elderly population during a Gamma variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study – medRxiv

 

Comentário no Twitter (fio – clique para saber mais)

 

Vacina CoronaVac: os resultados são conflitantes, mas o mundo não pode ignorar sua utilidade.

27 Jul, 2021 | 10:23h

CoronaVac vaccine: its results are patchy, but the world can’t ignore its usefulness – The Conversation

Conteúdos Relacionados:

RCT: CoronaVac showed efficacy of 83.5% for preventing symptomatic SARS-CoV-2 infection.

Prospective national cohort in Chile showed CoronaVac effectiveness was 65.9% for symptomatic Covid-19, 87.5% for hospitalization, 90.3% for ICU admission, and 86.3% for death.

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

Perspective | Are Chinese COVID vaccines underperforming? a dearth of real-life studies leaves unanswered questions.

WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic.

Brazilian town experiment shows mass vaccination can wipe out COVID-19.

WHO validates Sinovac-CoronaVac COVID-19 vaccine for emergency use and issues interim policy recommendations.

[Press release – not published yet] The city of Serrana in Brazil has seen a 95% drop in Covid-19 deaths after almost all adults were vaccinated with Chinese CoronaVac – The findings suggest the pandemic can be controlled after 75% of people are fully vaccinated.

[Not published yet] Observational study in Uruguay found CoronaVac reduced mortality by 97 percent – “In people who had received two doses, it reduced infection with the coronavirus by 57 percent and intensive care admissions by 95 percent”.

M-A | Pacientes psiquiátricos têm risco aumentado de hospitalização e morte por COVID-19.

26 Jul, 2021 | 10:20h

Comunicado de imprensa: Psychiatric patients at increased risk of COVID-19 hospitalization and mortality – European College of Neuropsychopharmacology

Artigo original: Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis – The Lancet Psychiatry

Estudo mostra que o teste de antígeno de fluxo lateral pode detectar, de modo rápido e acurado, a COVID-19 inicial em pacientes com sintomas gripais e pode ser uma alternativa plausível ao RT-PCR.

26 Jul, 2021 | 10:19h

Comparing the diagnostic accuracy of point-of-care lateral flow antigen testing for SARS-CoV-2 with RT-PCR in primary care (REAP-2) – EClinicalMedicine

Comunicado de imprensa: Lateral flow tests are 95% effective at detecting Covid-19 when used at the onset of symptoms – University of Oxford

Relacionado:

Interactive Infographic | Interpreting a lateral flow SARS-CoV-2 antigen test – “This calculator demonstrates how interpreting a covid-19 lateral flow device (LFD) result varies according to the pre-test probability, and the sensitivity and specificity of the LFD used”.

Rapid point-of-care tests for diagnosing COVID-19 infection: the latest Cochrane evidence

 

Comentário no Twitter (fio – clique para saber mais)

 

Vacinas contra COVID talvez cheguem aos países mais pobres somente em 2023 – “Especialistas afirmam que, em meio ao aumento da COVID na África, a promessa de vacinas vindo de nações mais ricas não é suficiente para acabar com a pandemia.”

26 Jul, 2021 | 10:15h

COVID vaccines to reach poorest countries in 2023 — despite recent pledges – Nature

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.